Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.75 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.75 |
| ▸ | ITGAV | P06756 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716140 | 1.00 | ITGB3 (0.75) | ITGB3ITGA2BITGAVMAPTL3MBTL1 | |
| SCHEMBL26966055 | 0.96 | ITGB3 (0.72) | ITGB3ITGA2BITGAVMAPTL3MBTL1 | |
| SCHEMBL27131049 | 0.96 | ITGB3 (0.72) | ITGB3ITGA2BITGAVMAPTL3MBTL1 | |
| SCHEMBL30149863 | 0.94 | ITGB3 (0.67) | ITGB3ITGA2BITGAVMAPTL3MBTL1 | |
| SCHEMBL7402776 | 0.93 | ITGB3 (0.72) | ITGB3ITGA2BITGAVMAPTPTPN1 | |
| SCHEMBL9161400 | 0.93 | ITGB3 (0.72) | ITGB3ITGA2BITGAVMAPTPTPN1 | |
| SCHEMBL29260893 | 0.93 | ITGB3 (0.66) | ITGB3ITGA2BITGAVMAPTL3MBTL1 | |
| Potassium Ion SCHEMBL29260880 | 0.92 | ITGB3 (0.64) | ITGB3ITGA2BITGAVMAPTL3MBTL1 | |
| SCHEMBL30638155 | 0.89 | ITGB3 (0.63) | ITGB3ITGA2BMAPTL3MBTL1 | |
| SCHEMBL7490606 | 0.88 | ITGB3 (0.64) | ITGB3ITGA2BITGAVMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084735-A | Photo-delay synthesis method of O- [2- [ [ tert-butyloxycarbonyl ] amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine | 吉尔多肽生物制药(大连市)有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | ITGB3 2795/4885ITGA2B 3410/4885ITGAV 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.